Welcome To Equilab International

Supported by our experiences and capabilities, we are the leader in the field of bioavailability and bioequivalence (BA/BE) studies and clinical trial services in Indonesia and Southeast Asia. 
 
Established in 2003 as the first independent Bioequivalence Center in Indonesia, Equilab International has been providing our service for local and international pharma company in Asia, Australia, America, Africa, and Europe. 
 
Our Bioequivalence Study Reports have been approved by regulatory body in UK, Netherland, Poland, Indonesia, Malaysia, Philippines, Singapore, Vietnam, Myanmar, Cambodia, Srilanka, Bangladesh, Taiwan, Hongkong, and Afghanistan.
 
More than 562 studies have been completed to date and there are around 80 studies on process currently.
 
Equilab International is your chosen partner because we provide :
  • In-Depth understanding of Local Regulatory (BPOM and Ethics Committee)
  • Accredited bioanalytical laboratory, with 203 validated methods applicable (ISO 17025:2017)
  • Clinical site with 75 beds capacity, with accredited in house clinical laboratory (ISO 15189:2012)
  • Reliable bioanalytical instruments : 7 LCMS/MS and 3 HPLC UV/FL
  • Solid experience in biostatistics and PK groups to design studies and analyse data using WinNonlin 8.2 as recognized by USFDA, UKMHRA, and WHO
  • A guaranteed data integrity using NuGenesis 8
 
Contact us today to disscussed how we can collaborate with you!
 
Category: